Takeda joins forces with small private biotech for preclinical Alzheimer's research
Takeda is wading deeper into Alzheimer’s disease research with a new preclinical collaboration announced Tuesday.
The company will work with Treventis, a little-known private biotech from Toronto, on a small molecule program targeting the tau protein. Treventis CEO Christopher Barden tells Endpoints News the biotech is still working on selecting which drug candidate to move forward and will use Takeda’s help to make that choice. Takeda can then option it into further preclinical, and potentially clinical, studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.